Drug recall · March 27, 2024
Digoxin Tablets recall
Why: Cross Contamination with Other Products:(mycophenolate mofetil).
Class III: unlikely to cause harm, but breaks the rules (for example a labeling error).
The recall
- Product
Digoxin Tablets, USP 125mcg, (0.125 mg), 1000-count bottle, Rx Only, Manufactured by: Novitium Pharma LLC., 70 Lake Drive, East Windsor, New Jersey 08520, NDC 70954-201-20
- Lots / codes
Lot #: M23172A, Exp 01/31/2025
- Quantity
- 3,940 1000-count bottles
- Company
- Novitium Pharma LLC, East Windsor, NJ
- Distribution
- Nationwide in the USA
- Initiated
- March 4, 2024 · Voluntary: Firm initiated
- Classified
- March 15, 2024
- Reported
- March 27, 2024
- Ended
- March 21, 2025
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Digoxin
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.